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Orthosiphon stamineus is a popular folk medicine widely used to treat many diseases in-
cluding diabetes. Previous studies have shown that the sub-fraction of chloroform extract
was able to inhibit the rise of blood glucose levels in a glucose tolerance test. This study
was carried out to evaluate the chronic effect and possible mechanism of action of the
bioactive chloroform sub-fraction of O. stamineus using streptozotocin-induced diabetic
rats and in vitro methods. Administration of the chloroform extract sub-fraction 2 (Cf 2-b)
at a dose of 1 g/kg twice daily on diabetic rats for 14 days showed a significant lowering
(p < 0.05) of the final blood glucose level compared to the pretreatment level. However,
there were no significant differences in the plasma insulin levels post-treatment com-
pared to the pretreatment levels for all doses of Cf 2-b. Conversely, Cf2-b at a concentra-
tion of 2 mg/mL significantly increased (p < 0.001) the glucose uptake by the rat
diaphragm muscle. The increase in glucose uptake was also shown when the muscle
was incubated in a solution containing 1 IU/mL of insulin or 1 mg/mL of metformin.
Furthermore, the effect of this sub-fraction on glucose absorption in the everted rat
jejunum showed that Cf2-b at concentrations of 0.5 mg/mL, 1 mg/mL and, 2 mg/mL
significantly reduced the glucose absorption of the jejunum (p < 0.05e0.001). Similarly,
the absorption of glucose was also inhibited by 1 mg/mL and 2 mg/mL of metformin
(p < 0.001). These results suggest that the effect of Cf 2-b may be due to extra-
pancreatic mechanisms. There was no evidence that the plant extract stimulated the
release of insulin in order to lower the blood glucose level.armaceutical Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia.
acopuncture Institute
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32 E.A.H. Mohamed et al.1. Introduction determined using the Accu-chek Advantage II Clinical Glu-The pathogenesis of diabetes mellitus and possibility of its
management by the oral administration of antidiabetic
agents, including those from folk medicines, have stimu-
lated great interest in recent years. Orthosiphon stamineus
Benth [syn: Orthosiphon aristatus (B1) Miq., Orthosiphon
grandiflorus Bold., Orthosiphon spicatus (Thumb.) Bak.;
Lamiaceae] [1] is one of the popular traditional folk med-
icines extensively used in Southeast Asia for the treatment
of a wide range of diseases. It is used: (1) in Indonesia for
rheumatism, diabetes, hypertension, tonsillitis, epilepsy,
menstrual disorder, gonorrhea, syphilis, renal calculus, and
gallstones [2], (2) in Vietnam for urinary lithiasis, edema,
eruptive fever, influenza, hepatitis, jaundice, and biliary
lithiasis [3], and (3) in Myanmar to alleviate diabetes, and
urinary tract and renal diseases [4,5].
Due to its popularity and demonstrated effectiveness,
phytochemical [6e8] and pharmacological studies [9e11] of
this plant have been conducted since 1930. Highly-
oxygenated isopimarane-type diterpenes, known as orthosi-
phols AeE, have been isolated, togetherwithmonoterpenes,
triterpenes, saponins, flavonoids, hexoses, organic acids,
rosmarinic acid, chromene, and myo-inositol. O. stamineus
has also been reported to possess hypoglycemic and anti-
hyperglycemic activities [12], and an aqueous extract
exhibited a hypoglycemic effect in normal and streptozoto-
cin (STZ)-induced diabetic rats, respectively. The present
study tried to elucidate the antihyperglycemic or hypogly-
cemic effects of the plant on normal anddiabetic ratswhen it
has been extracted serially with different solvents. This
method of extraction helps to streamline the chemical con-
tents of theplant according to thepolarity of the solvent. The
profile and thedynamics of theblood glucose level of extract-
treated rats were then determined using a subcutaneous
glucose tolerance test. Theoretically, these tests should be
able to screen hypoglycemic and antihyperglycemic agents.
A hypoglycemic agent is an agent that is capable of reducing
the blood glucose level below fasting levels, whereas anti-
hyperglycemic agents lower the blood glucose level but not
beyond the fasting level. Glibenclamide is a hypoglycemic
agent, while metformin is antihyperglycemic or euglycemic
agent.
The aim of the present study was to evaluate the anti-
hyperglycemic activity of a sub-fraction (Cf2-b) of chloro-
form extract from O. stamineus in normal and STZ-induced
diabetic rats. The effects of this sub-fraction on the uptake
of the glucose in the muscle and the inhibition of the glu-
cose absorption in the gastrointestinal tract were also
investigated (Fig. 1).
2. Materials and methods
2.1. Chemicals
Metformin (UPHA, Malaysia), glibenclamide (Hovid, Malay-
sia), STZ (Sigma, USA), and human insulin 100 IU/mL (Novo
Nordisk, Denmark) were all used, and analyses were per-
formed using thin layer chromatography (TLC plate Art-5554,
Merck, Darmstadt, Germany; Fig. 2) and high-performance
liquid chromatography (HPLC). Blood glucose levels werecose meter (Roche Diagnostics Co. USA). The insulin con-
centration in the plasma samples was assayed by enzyme-
linked immunoassay (ELISA) using a Rat Insulin ELISA Kit
(Crystal Chem, IL, USA).
2.2. Animals
The normoglycemic female Sprague-Dawley rats weighing
200e250 g used in this study were obtained from the animal
house of the School of Pharmaceutical Sciences, Universiti
Sains Malaysia, Penang. The animals were kept at 25e30 C,
acclimatized with free access to food (normal laboratory
chow, Gold Coin) and water ad libitum for 1 week under
a 12-hour light, 12-hour dark cycle. All animals were care-
fully monitored and all of the experimental work with the
animals was carried out after obtaining approval from the
Universiti Sains Malaysia Animal Ethical Committee. For
experimental purposes, animals were fasted overnight but
had free access to water.
2.3. Plant material and preparation of the active
fraction
O. stamineus Benth was collected from Kepala Batas, Pulau
Pinang Malaysia. The plant was identified and a voucher
specimen (No: 10810) was deposited at the herbarium at
the School of Biological Sciences, Universiti Sains Malaysia.
The plant material was prepared according to a previously
performed guided fractionation of this plant [13]. It was
found that the most active antihyperglycemic principles
were in sub-fraction Cf2-b of the chloroform extract. The
Cf2-b obtained was filtered and the solvent evaporated
under vacuum using Rotavapor (Buchi, Switzerland). The
extract was then frozen and freeze-dried (Labconco
Cooperation, Denmark) at 40 C for 24 hours to give
a dried extract. The dried extract was stored in an airtight
container, labeled and stored until use [13].
2.4. Phytochemical investigation of active sub-
fraction Cf2-b
Phytochemical tests were carried out to identify the various
constituents of sub-fraction Cf2-b and were compared to
the reference compound (sinensetin) using the following
chemical reagents: Dragendorff’s reagent was used to
determine the presence of alkaloids; a natural product
reagent was used for flavonoids; the reagent antimony tri-
chloride was used for terpenoids; and sulfuric acid was used
for coumarins [14].
2.5. High-performance liquid chromatography
study of Cf2-b
HPLC analysis was performed using a Shimadzu LC system
(Shimadzu, Japan) equipped with a CBM-20A controller,
dual LC-20AT pumps, a DGU-20A5 degasser, an SIL-20A auto-
sampler, a SPD-20AV detector, and a CTO-10ASvp column
oven. Chromatographic separations were achieved using
an Agilent Eclipse Plus C18 (250  4.6 mm i.d.; 5 mm)
Figure 1 Schematic diagram of the antidiabetic study of Orthosiphon stamineus.
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fitting kit packed with a replaceable Eclipse Plus C18 Guard
column (12.5  4.6 mm i.d.; 5 mm) (Agilent Technologies,
California, USA) was used to protect the analytical column.
A reverse-phase HPLC assay was carried out using an iso-
cratic system with a flow rate of 1 mL/min, a column
temperature of 25 C, and a mobile phase of acetonitrile,
isopropyl alcohol and 0.02 M phosphate buffer (NaH2PO4)
(30:15:55, v/v) with pH adjusted to 3.5 using 85% phos-
phoric acid. The ultraviolet detection was set at 340 nm.
The injection volume was 20 ml. The total run time was less
than 20 minutes for each injection. Data were acquired and
processed using LC-Solution Software. The peaks were
detected at 340 nm and identified using standard sub-
stances, namely sinensetin, eupatorin, and 30-hydroxy-
5,6,7,40-tetramethoxyflavone [15].
2.6. In vivo studies
2.6.1. Induction of experimental diabetes
Hyperglycemia was induced in rats via a single intra-
peritoneal injection of STZ (65 mg/kg) [16]. The STZ was
freshly dissolved in citrate buffer (0.01 M, pH 4.5) [17] and
kept on ice prior to use. The injection volume was 1 mL/kg[18,19]. One week after STZ administration, the blood
glucose was measured and the animals were considered to
have diabetes if the fasting blood glucose value was over
16.7 mmol/L [19,20].
2.6.2. The repeated administration of Cf2-b in diabetic
rats
Diabetes was successfully induced in 24 Sprague-Dawley rats
(200e250 g) and these animals were randomly divided into
four groups of six rats (nZ 6). The groups were treated with
either 5mL/kgof normal saline as a negativecontrol, 500mg/
kg of metformin as a positive control, or a sub-fraction Cf 2-
b of O. stamineus extract (0.5 g/kg and 1.0 g/kg) orally
twice daily for 14 days. The fasting blood glucose levels were
measured after confirmation of diabetes and 14 days after
the chronic oral treatment for comparison.
2.6.3. Determination of blood glucose and serum insulin
levels
Blood samples were obtained from the tail vein of the dia-
betic rats at the beginning of the experiment and 14 days
after the twice-daily treatment. A drop of blood was used
each time for the determination of blood glucose levels using
the Accu-chek Advantage II Clinical Glucose meter. In order
Figure 2 The thin-layer chromatography profile of sub-
fraction (Cf 2-b) and sinensetin (SEN) after being developed
with ethyl acetate:chloroform (75:25) as a mobile phase and
sprayed with a natural product (NP/PEG) reagent under (A)
visible light and (B) ultraviolet 365 nm.
Figure 3 The thin-layer chromatography profile of sub-
fraction (Cf 2-b) and sinensetin (SEN) after being developed
with ethyl acetate:chloroform (75:25) as a mobile phase and
sprayed with an antimony trichloride reagent under (A) visible
light (B) ultraviolet 365 nm.
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a 75 mL blood sample was collected into hematocrit-capillary
tubes (Hirschmann Laborgerate GmbH & Co. KG, Eberstadt,
Germany) and centrifuged at 5000 rpm for 3e5 minutes. The
plasma samples obtained were stored at 20 C until they
were measured for insulin concentration. The insulin con-
centration in the plasma samples (5 mL) was assayed by ELISA
using a Rat Insulin ELISA Kit.
2.7. In vitro studies
2.7.1. Measurement of glucose absorption in the everted
rat jejunum
Female Sprague-Dawley rats weighing 150e200 g were fas-
ted for 16 hours before the experiment. They were then
killed by a blow to the head, and dissected to remove the
small intestine [21]. Segments located between 24.0 cm and
34.5 cm (jejunum) and 84.0e94.5 cm away from pylorus
(ileum) [22] were excised, and placed in ice-cold Krebs
Ringer solution (154 mM NaCl, 5.6 mM KCl, 5.5 mM glucose,
20.1 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid, and 25 mM NaHCO3, adjusted to pH 7.4 with NaOH).
Then, the segments were rinsed with the buffer and everted
onto a glass rod. They were then cut into 10 cm pieces
(nZ 6), rinsed and placed on filter paper to dry before being
weighed. Each piece of the intestine was tied tightly around
one end with a thread, while the other end only required
a loose knot. Two milliliters of glucose-Ringer solution was
injected into each sample using a slipping blunt needle, andthe knot was then tightened before any excess tissue was
trimmed off at each end. The jejunum samples were incu-
bated in 30 mL of the following Krebs Ringer solutions in
50 mL beakers:
 Krebs Ringer solution (control);
 Krebs Ringer solution þ different concentrations of
metformin;
 Krebs Ringer solution þ different concentrations of
glibenclamide; and
 Krebs Ringer solution þ different concentrations of Cf 2-
b of O. stamineus.
The preparations were kept in an atmosphere of 95%
oxygen and 5% carbon dioxide at 37 C throughout the
experiment. At the end of the 90-minute incubation period,
the glucose concentration of the inside sacs and the incu-
bation media were determined using the Accu-chek
Advantage II Clinical Glucose meter. Results are expressed
as mg of glucose absorption or amount of glucose trans-
ported/mg of tissue weight.
2.7.2. Measurement of glucose uptake in an isolated rat
hemi-diaphragm
Glucose absorption by the rat diaphragm was examined
according to the method devised by Frayn and Adnitt [23].
Rats weighing 150e200 g were killed by a blow to the head
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was rinsed in ice-cold Krebs Ringer solution and then cut into
two equal hemi-diaphragms, gently blotted and weighed.
One hemi-diaphragm was placed in a small conical flask
containing 2 mL of Krebs Ringer solution in an atmosphere of
95% O2 and 5% CO2. The other hemi-diaphragm from the
same animal was placed into Krebs Ringer solution con-
taining the test substance. The tissues were constantly
shaken at 37 C and incubated for 90 minutes. Duplicate
samples of each medium were taken for glucose estimation
before the placement of the tissue and at the end of the
experiment. One hemi-diaphragm was used as a control and
the other hemi-diaphragm from the same animal was used
for the test experiment (using Cf2-b of the O. stamineus
extract). Equal numbers of left and right hemi-diaphragms
were used for controls and test samples, respectively. The
results obtained were expressed as the amount of glucose
utilized by the hemi-diaphragms in 1 mg of glucose per gram
of tissue during the 90-minute incubation period. TheFigure 4 (A) High-performance liquid chromatogram of standar
(TMF), sinensetin (SEN), and eupatorin (EUP) are indicated. (B) Hi
SEN, and EUP are indicated.glucose concentration was measured using the Accu-chek
Advantage II Clinical Glucose meter.
2.8. Statistical analysis
Statistical analysis of data was performed using the one-
way analysis of variance, independent-sample t test and
paired-sample t tests. The differences between the means
were considered significant at the probability level
p < 0.05. The statistical analysis was performed using the
computer program SPSS (Release 11.5, SPSS Inc., 2001).
3. Results
3.1. Phytochemical investigation of Cf2-b
Phytochemical screening of Cf2-b in the present study
indicated the presence of terpenoids and flavonoids, withd markers. Peaks for 30-hydroxy-5,6,7,40-tetramethoxyflavone
gh-performance liquid chromatogram of Cf2-b. Peaks for TMF,
Figure 6 The effects of the oral administration of sub-
fraction Cf2-b (0.5 g/kg and 1 g/kg) twice daily for 14 days
on insulin levels of streptozotocin-induced diabetic rats. The
values are presented as mean  S.E.M. (n Z 6).
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ever, alkaloids and coumarins were absent (Figs. 1 and 3).
3.2. High-performance liquid chromatography
analysis
The percentages of sinensetin, eupatorin, and 30-hydroxy-
5,6,7,40-tetramethoxyflavone in Cf 2-b were 1.48%, 2.26%,
and 0.58%, respectively (Fig. 4).
3.3. In vivo studies
3.3.1. The effect of repeated administration of Cf2-b on
the blood glucose and insulin levels of diabetic rats
The twice-daily oral treatment with Cf 2-b at 1.0 g/kg for 14
days caused a significant decrease (p < 0.05) in blood glu-
cose levels in the post-treatment samples, compared to the
pretreatment levels of diabetic rats (Fig. 5). Similarly,
metformin (500 mg/kg) caused a significant lowering
(p < 0.001) of blood glucose levels at the post-treatment
compared to the pretreatment level (Fig. 6). Fig. 6, how-
ever, shows that no significant increase was found in the
post-treatment plasma insulin levels compared to the pre-
treatment levels of the metformin 500 mg/kg- and Cf2-
b 1.0 g/kg-treated groups.
3.4. In vitro studies
3.4.1. The effects of sub-fraction Cf2-b on glucose
absorption in the everted rat jejunum
Fig. 7A shows that the everted small intestine absorbed
glucose during incubation in Krebs solution over a 90-
minute period. The addition of glibenclamide at concen-
trations of 0.01 mg/mL, 0.1 mg/mL, and 1 mg/mL did not
significantly change the amount of glucose absorbed. By
contrast, incubation in metformin 0.5 mg/mL began to
reduce the amount of glucose absorbed, although this was
not statistically significant (Fig. 7B). Moreover, theFigure 5 The effects of the oral administration of sub-
fraction Cf2-b (0.5 g/kg and 1 g/kg) on the blood glucose
levels of streptozotocin-induced diabetic rats, twice daily for
14 days. The values are presented as mean  S.E.M. (n Z 6).
* Significant difference (p < 0.05); ** significant difference
(p < 0.01) between pretreatment and post-treatment.increased concentration of metformin of 1 mg/mL sig-
nificantly (p < 0.05) inhibited the absorption of glucose in
the everted small intestine. Further doubling of the con-
centration of metformin to 2 mg/mL reduced the extent of
the inhibition of glucose absorption, although it was still
statistically significant (p < 0.05) when compared to Krebs
Ringer solution alone. The amount of glucose absorption of
the everted small intestine was also significantly (p < 0.05)
inhibited by sub-fraction Cf2-b at concentrations of
0.5 mg/mL, 1.0 mg/mL, and 2 mg/mL (Fig. 7C). Similar to
Fig. 7B, the addition of metformin 1 mg/mL significantly
inhibited (p < 0.05) glucose absorption by the intestine in
the Krebs Ringer solution (Fig. 7D). However, the further
addition of sub-fraction 2 mg/mL of Cf 2-b in the Krebs
Ringer solution containing metformin 1 mg/mL did not
inhibit the absorption further (Fig. 7D).
3.4.2. The effects of sub-fraction Cf2-b on glucose
uptake in the isolated rat hemi-diaphragm
The uptake of glucose by the hemi-diaphragm in the Krebs
solution was not significantly increased by metformin
0.01 mg/mL or 0.1 mg/mL. The higher concentration of 1
mg/mL of metformin, however, significantly increased
(p < 0.05) the uptake of glucose by the hemi-diaphragms
during the 90-minute incubation period (Fig. 8A). Fig. 8B
shows that the uptake of glucose from the incubation media
(Krebs Ringer solution) by hemi-diaphragms in the presence
of insulin 1 IU/mL was significantly higher (p < 0.05) than in
the Krebs Ringer solution alone. The addition of metformin
1 mg/mL in the Krebs solution containing insulin 1 IU/mL
significantly (p < 0.05) increased the uptake of glucose
compared to the Krebs Ringer solution containing same
amount of insulin (Fig. 8C). By contrast, the uptake of
glucose by the hemi-diaphragm during the 90-minute in-
cubation period was not significantly increased by sub-
fraction Cf2-b 0.5 mg/mL and 1 mg/mL. However, when
incubated in the presence of a higher concentration of Cf2-
b (2 mg/mL), the glucose utilized by the hemi-diaphragm
was significantly higher (p < 0.05) than in the Krebs
Ringer solution alone (Fig. 8D). Although the utilization of
glucose by the hemi-diaphragm was increased in the
Figure 7 The effect of different concentrations of (A) glibenclamide, (B) metformin, (C) sub-fraction (Cf 2-b), and (D) sub-
fraction (Cf2-b) 2 mg/mL and metformin 1 mg/mL on the glucose absorption of isolated everted rat small intestine
incubated for 90 minutes in Krebs solution. The values are presented as mean  S.E.M. (nZ 6). * Significant difference (p < 0.05);
** significant difference (p < 0.01) between the control group and glibenclamide, metformin, and Cf 2-b treated groups.
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of sub-fraction Cf 2-b 2 mg/mL in the presence of insulin
1 IU/mL did not significantly change the amount of glucose
uptake as compared to the Krebs Ringer solution containing
same amount of insulin (Fig. 8E).4. Discussion
The use of STZ to induce diabetes in rats was widely utilized
due to its specificity in destroying only the b-cells of the
islets of Langerhans. The intermediate dose of 65 mg/kg
intraperitoneally manages to induce the diabetic state, and
the rats were able to survive without insulin supplemen-
tation up to the end of the 14-day study period. This finding
corresponded with those of Junod et al and Ar’Rajab and
Ahren [24,25]. A novel result reported in the present study
indicates that the twice daily treatment with a sub-fraction
of chloroform extract from O. stamineus (Cf 2-b) at a dose
of 1.0 g/kg for 2 weeks results in the reduction of fasting
blood glucose level in STZ-induced diabetic rats. This
finding is in line with that of Mariam et al [12], who
reported that the aqueous extract of the O. stamineus
plant reduced the blood glucose level of STZ-induced dia-
betic rats.
The blood glucose level of the post-treatment animals
after a repetitive dose regimen with metformin was sig-
nificantly lower compared to the pre-treatment level. This
result is similar to that found by Zhang and Tan [26]. Thelowering of blood glucose levels after repeated doses of
metformin in diabetic rats is not expected, as the anti-
diabetic drug metformin, a biguanide, is not known to
stimulate the release of insulin from pancreatic b-cells. The
lowering of blood glucose levels by metformin was pre-
sumably a result of the physiological response of several
tissues, including increases of glucose uptake by skeletal
muscle and adipose tissue [27,28]. In a previous work [13],
it was reported that Cf 2-b produced an antihyperglycemic
effect in a subcutaneous glucose tolerance test in normal
rats. The effect of Cf 2-b mimicked the effect of metformin;
it has no hypoglycemic effect in normal rats but an anti-
hyperglycemic effect in the glucose tolerance test. This
suggests that the extract may have no direct stimulatory
effect on insulin secretion, similar to metformin.
The possible mechanism of action of Cf2-b was studied
using in vitro model techniques. In order to study glucose
transport in peripheral tissues in vitro, the commonly used
techniques involved cultures of skeletal muscle strips or
cells, and the isolated diaphragm from rat [23] or from
humans obtained by surgical excision [29]. The effects of
natural products on glucose uptake and metabolism in pe-
ripheral tissues have also been studied using fragments or
a homogenate of the rat small intestine [30]. Among these
methods, the isolated rat diaphragm and everted rat jeju-
num methods were chosen in the present study to evaluate
the glucose uptake and glucose absorption, respectively, in
an attempt to elucidate the mechanisms of action of the
antihyperglycemic agents of Cf 2-b. The previous study
Figure 8 The effect of (A) metformin, (B) insulin, (C) metformin (Met þ Ins), (D) sub-fraction (Cf 2-b), and (E) sub-fraction (Cf 2-b)
on the glucose uptake of isolated rat hemi-diaphragm incubated at 37 C for 90 minutes in Krebs solution. The values are presented
as mean  S.E.M. (n Z 6). * Significant difference (p < 0.05); ** significant difference (p < 0.01) between the control group and
metformin, insulin and Cf 2-b treated groups.
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of this preparation for comparative studies of insulin and
other drug actions, as well as the insulin-like effects of
other natural products [31]. The effect of Cf 2-b was
examined at 0.5 mg/mL, 1 mg/mL, and 2 mg/mL in order to
study its effect on glucose uptake by the isolated skeletal
muscle of the rat diaphragm in the absence and presence of
insulin. In the absence of insulin, sub-fraction Cf 2-
b induced a dose-dependent increase in glucose uptake
by the diaphragm, which means that Cf 2-b may act like
insulin regarding the uptake of glucose, by facilitating
glucose transport across plasma membranes into cells or by
increasing glucose transport into the cells, which increases
the metabolism of carbohydrates. In the presence of both
insulin and Cf2-b, the utilization of glucose was not
further increased, which means that Cf2-b might not
improve insulin action in the muscle. Instead, it suggests
that Cf 2-b has an antihyperglycemic effect due to its
extra-pancreatic action. One of the extra-pancreatic ac-
tions occurs as a result of stimulating glucose utilization in
peripheral tissues, such as the diaphragm [32,33]. The
above findings indicate that the effects of Cf2-b on glucose
uptake are probably the result of a direct insulin-like effecton the utilization of glucose, which occurs by increasing the
membrane transport of glucose in peripheral tissues. Sim-
ilarly, metformin at a concentration of 1 mg/mL increased
glucose uptake by the diaphragm in the absence of insulin.
This metformin-induced improvement in glucose disposal
has been attributed predominantly to the action of met-
formin, which facilitates the translocation of glucose
transporters from intracellular sites to the plasma mem-
brane of rat skeletal muscle [34] and increases their
intrinsic activity [35]. This finding is in accordance with
previous studies in which various concentrations of met-
formin were used [23]. In the present study, however,
metformin at a concentration of 1 mg/mL in the presence
of insulin at 1 IU/mL further increased the glucose utiliza-
tion. These results are in agreement with the previous
study by Frayn and Adnitt [23], which showed that met-
formin not only enhanced the peripheral utilization of
glucose, but also improved the insulin action in muscle and
fat tissues. This was attributed, in part, to the increased
movement of insulin-sensitive glucose transporters into
the cell membrane. Another action of metformin involves
the insulin-independent suppression of fatty acid oxidation
and a reduction in hypertriglyceridemia. The possible
Antidiabetic effect of O. stamineus 39mechanism of action of Cf2-b in this case is probably its
immediate membrane effect, which results in increasing
glucose transport as well glucose utilization, especially by
muscle. One possible action of Cf2-b is the direct insulin-
like effect on the utilization of glucose, resulting in an
increase in the uptake of glucose into muscle and adipose
tissue. It is a crucial component of the physiological
response to insulin.
In the everted rat jejunum, the results clearly show that
Cf2-b at concentrations of 0.5 mg/mL, 1 mg/mL, and
2 mg/mL inhibited intestinal glucose absorption. Similarly,
it was found that the absorption of glucose was also
inhibited by metformin. The finding that metformin
inhibited glucose absorption is in agreement with the
findings of the previous studies by Klip and Leiter [35],
Caspary and Creutzfeldt [36], Lorch [37], and Bailey [38]. In
addition, Wilcock and Bailey [39] demonstrated that met-
formin decreases glucose transport in the inverted sacs of
the intestine from hamsters, rats, and mice. The present
results are consistent with their studies. Furthermore, the
lowest dose of metformin (0.5 mg/mL) failed to inhibit
glucose absorption while the highest dose (2 mg/mL)
inhibited the glucose absorption by less than the 1 mg/mL
dose. The extent of the inhibition by metformin may
therefore depend upon the concentration of metformin.
Love reported that metformin inhibits glucose absorption in
the everted rat jejunum at concentrations greater than
1.5 mg/mL or 2 mg/mL, but causes increased absorption of
glucose when present at lower concentrations [40]. Lenzen
et al reported that metformin significantly increased the
energy-dependent sodium-hexose cotransporter (SGLT1)
gene expression and facilitative hexose transporter GLUT5
gene expression in the jejunum [41]. This offers the po-
tential for an increase in hexose uptake at the brush border
membrane. Increased intestinal glucose utilization by
metformin would be expected to consume a greater pro-
portion of the intracellular glucose taken up from the
jejunum, which accounts, at least in part, for the apparent
reduction in glucose transport [42]. Since glucose absorp-
tion from the intestine was decreased significantly by
metformin as well as Cf2-b, the efficacy of Cf2-b may also
be due to the increase in the gene expression of SGLT1 and
GLUT5 in the rat jejunum enterocytes. This offers the po-
tential for an increase in hexose uptake at the brush border
membrane, and may compensate for other effects of the
Cf2-b that suggest a decrease in glucose absorption by
SGLT1. Thus, the inhibition of glucose absorption when Cf 2-
b is in direct contact with the brush border membrane of
the rat small intestine might be one of the possible mech-
anisms responsible for its antihyperglycemic activities. In
this case, one possible mechanism of the antihyperglycemic
effect of Cf 2-b is related to the inhibition of the active
transport of intestinal glucose absorption, which is similar
to metformin.
Thin layer chromatography screening of Cf2-b indicated
the presence of terpenoids and flavonoids. HPLC analysis
also indicated that flavonoids, namely sinensetin, eupa-
torin, and 30-hydroxy-5,6,7,40-tetramethoxyflavone, are
present in Cf2-b. Since previous studies have indicated
that flavonoids and terpenoids produce antidiabetic activ-
ity [43e45], these compounds could be responsible for
the antihyperglycemic effect of Cf2-b, whether actingseparately or synergistically. Although Cf2-b may have no
direct stimulatory action on insulin secretion, it might
produce the antihyperglycemic effect through an extra-
pancreatic mechanism. Another possible mechanism
observed in the present study by which Cf 2-b exerts an
antihyperglycemic effect is by inhibition of the active
transport of intestinal glucose absorption. The findings of
the present study suggest that the extract may be effective
in non-insulin dependent diabetes mellitus.References
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